| UK launch for Boehringer Ingelheim/Eli Lilly's Trajenta - Pharma Times |
|
|
Pharma Times Linagliptin is the only DPP-4 inhibitor primarily excreted via the bile, and the first treatment in this class licensed for use in T2DM irrespective of degree of renal impairment, with no dose adjustment or additional treatment-related monitoring |